ANTI-SEMA3A ANTIBODIES AND USES THEREOF
The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | ELLINGER, Philipp FILARSKY, Katharina MCALEESE ESER, Fionnuala Mary WEBER, Ernst FLAMME, Ingo SEDAGHAT, Yalda SCHMIDT, Antje WUNDERLICH, Winfried DRÖBNER, Karoline SCHÖNFELD, Dorian YOUNG, Kenneth |
description | The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4314047A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4314047A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4314047A13</originalsourceid><addsrcrecordid>eNrjZFB39Avx1A129XU0dlQAsZ38XTxdg4FMF4XQYCAjxMM1yNXfjYeBNS0xpziVF0pzMyi4uYY4e-imFuTHpxYXJCan5qWWxLsGmBgbmhiYmDsaGhOhBACABCMZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><source>esp@cenet</source><creator>ELLINGER, Philipp ; FILARSKY, Katharina ; MCALEESE ESER, Fionnuala Mary ; WEBER, Ernst ; FLAMME, Ingo ; SEDAGHAT, Yalda ; SCHMIDT, Antje ; WUNDERLICH, Winfried ; DRÖBNER, Karoline ; SCHÖNFELD, Dorian ; YOUNG, Kenneth</creator><creatorcontrib>ELLINGER, Philipp ; FILARSKY, Katharina ; MCALEESE ESER, Fionnuala Mary ; WEBER, Ernst ; FLAMME, Ingo ; SEDAGHAT, Yalda ; SCHMIDT, Antje ; WUNDERLICH, Winfried ; DRÖBNER, Karoline ; SCHÖNFELD, Dorian ; YOUNG, Kenneth</creatorcontrib><description>The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240207&DB=EPODOC&CC=EP&NR=4314047A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240207&DB=EPODOC&CC=EP&NR=4314047A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ELLINGER, Philipp</creatorcontrib><creatorcontrib>FILARSKY, Katharina</creatorcontrib><creatorcontrib>MCALEESE ESER, Fionnuala Mary</creatorcontrib><creatorcontrib>WEBER, Ernst</creatorcontrib><creatorcontrib>FLAMME, Ingo</creatorcontrib><creatorcontrib>SEDAGHAT, Yalda</creatorcontrib><creatorcontrib>SCHMIDT, Antje</creatorcontrib><creatorcontrib>WUNDERLICH, Winfried</creatorcontrib><creatorcontrib>DRÖBNER, Karoline</creatorcontrib><creatorcontrib>SCHÖNFELD, Dorian</creatorcontrib><creatorcontrib>YOUNG, Kenneth</creatorcontrib><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><description>The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB39Avx1A129XU0dlQAsZ38XTxdg4FMF4XQYCAjxMM1yNXfjYeBNS0xpziVF0pzMyi4uYY4e-imFuTHpxYXJCan5qWWxLsGmBgbmhiYmDsaGhOhBACABCMZ</recordid><startdate>20240207</startdate><enddate>20240207</enddate><creator>ELLINGER, Philipp</creator><creator>FILARSKY, Katharina</creator><creator>MCALEESE ESER, Fionnuala Mary</creator><creator>WEBER, Ernst</creator><creator>FLAMME, Ingo</creator><creator>SEDAGHAT, Yalda</creator><creator>SCHMIDT, Antje</creator><creator>WUNDERLICH, Winfried</creator><creator>DRÖBNER, Karoline</creator><creator>SCHÖNFELD, Dorian</creator><creator>YOUNG, Kenneth</creator><scope>EVB</scope></search><sort><creationdate>20240207</creationdate><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><author>ELLINGER, Philipp ; FILARSKY, Katharina ; MCALEESE ESER, Fionnuala Mary ; WEBER, Ernst ; FLAMME, Ingo ; SEDAGHAT, Yalda ; SCHMIDT, Antje ; WUNDERLICH, Winfried ; DRÖBNER, Karoline ; SCHÖNFELD, Dorian ; YOUNG, Kenneth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4314047A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ELLINGER, Philipp</creatorcontrib><creatorcontrib>FILARSKY, Katharina</creatorcontrib><creatorcontrib>MCALEESE ESER, Fionnuala Mary</creatorcontrib><creatorcontrib>WEBER, Ernst</creatorcontrib><creatorcontrib>FLAMME, Ingo</creatorcontrib><creatorcontrib>SEDAGHAT, Yalda</creatorcontrib><creatorcontrib>SCHMIDT, Antje</creatorcontrib><creatorcontrib>WUNDERLICH, Winfried</creatorcontrib><creatorcontrib>DRÖBNER, Karoline</creatorcontrib><creatorcontrib>SCHÖNFELD, Dorian</creatorcontrib><creatorcontrib>YOUNG, Kenneth</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ELLINGER, Philipp</au><au>FILARSKY, Katharina</au><au>MCALEESE ESER, Fionnuala Mary</au><au>WEBER, Ernst</au><au>FLAMME, Ingo</au><au>SEDAGHAT, Yalda</au><au>SCHMIDT, Antje</au><au>WUNDERLICH, Winfried</au><au>DRÖBNER, Karoline</au><au>SCHÖNFELD, Dorian</au><au>YOUNG, Kenneth</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><date>2024-02-07</date><risdate>2024</risdate><abstract>The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre ; ger |
recordid | cdi_epo_espacenet_EP4314047A1 |
source | esp@cenet |
subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | ANTI-SEMA3A ANTIBODIES AND USES THEREOF |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T05%3A49%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ELLINGER,%20Philipp&rft.date=2024-02-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4314047A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |